


CERTIFICATE OF ELECTRONIC SUBMISSION	
September 21, 2006	
Date	Charles P. Landrum

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
McBride *et al.*

Serial No.: 10/701,038

Filed: November 4, 2003

For: P153 AND P156 ANTIGENS FOR THE
IMMUNODIAGNOSIS OF CANINE AND
HUMAN EHRlichioses AND USES
THEREOF

Group Art Unit: 1645

Examiner: Zeman, R.

Atty. Dkt. No.: CLFR:235US

SUPPLEMENTAL APPEAL BRIEF

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	REAL PARTY IN INTEREST.....	4
II.	RELATED APPEALS AND INTERFERENCES	4
III.	STATUS OF THE CLAIMS	4
IV.	STATUS OF AMENDMENTS.....	4
V.	SUMMARY OF CLAIMED SUBJECT MATTER.....	5
VI.	GROUND OF REJECTION TO BE REVIEWED ON APPEAL	7
VII.	ARGUMENT.....	7
	A. Rejections under 35 U.S.C. § 112	7
	1. Claims 6, 15, and 27-34 Satisfy the Written Description Requirement of 35 U.S.C. § 112, first paragraph.....	7
	2. Claims 6, 15, and 27-34 are Definite and Satisfy the Requirements of 35 U.S.C. § 112, second paragraph	11
	B. Objections under 37 C.F.R. § 1.175	12
	1. Claim 30 Further Limits the Subject Matter of Claim 6.....	12
	2. Claims 31, 32, 33, and 34 are Distinct from Claims 15, 27, 28, and 29	13
	C. Grouping of Claims	13
	D. Conclusion	13
VIII.	CLAIMS APPENDIX	15
IX.	EVIDENCE APPENDIX	17
X.	RELATED PROCEEDINGS APPENDIX.....	25

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
McBride *et al.*

Serial No.: 10/701,038

Filed: November 4, 2003

For: P153 AND P156 ANTIGENS FOR THE
IMMUNODIAGNOSIS OF CANINE AND
HUMAN EHRLICHIOSES AND USES
THEREOF

Group Art Unit: 1645

Examiner: Zeman, R.

Atty. Dkt. No.: CLFR:235US

SUPPLEMENTAL APPEAL BRIEF

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Appellants hereby submit this Supplement Appeal Brief to the Board of Patent Appeals and Interferences in response to the Notification of Non-Compliant Appeal Brief dated September 1, 2006.

It is believed that no additional fees are due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/CLFR:235US.

I. REAL PARTY IN INTEREST

The real party in interest is the assignee, Research Development Foundation, Carson City, Nevada.

II. RELATED APPEALS AND INTERFERENCES

There are no related appeals or interferences.

III. STATUS OF THE CLAIMS

Appellants originally filed claims 1-26. In the Response filed January 18, 2005 to the Restriction Requirement dated December 15, 2004 Applicants elected Group II, Claims 6 and 15, and elected to pursue SEQ ID NO: 2. Appellants withdrew claims 1-5, 7-14, and 16-26 from consideration. In the Response filed on September 19, 2005 to the Office Action dated April 25, 2005, which was supplemented with the Response of October 17, 2005 to Notice of Non-Compliant Amendment dated September 30, 2005, claim 6 was amended and new claims 27-34 were added. The Office Action dated January 9, 2006 maintained the rejection of claims 6, 15 and 27-34 as lacking written description. Thus, claims 6, 15 and 27-34 are currently pending, stand rejected, and are appealed. (*see* VIII. Claims Appendix).

IV. STATUS OF AMENDMENTS

The final Office Action mailed January 9, 2006 acknowledges the amendments included in the Response to Notice of Non-Compliant Amendment of October 17, 2005 and in the Response to Final Office Action of September 19, 2005. The Response of September 19, 2005 included amendment of claim 6 and the addition of claims 27-34. Applicants' Response on

March 9, 2006 to Final Office Action mailed January 9, 2006 contained claim amendments addressing all issues outstanding in the Final Office Action mailed January 9, 2006. The Advisory Action mailed March 31, 2006, denied entry of the March 9, 2006 amendments filed with the Response to Final Office Action filed March 9, 2006.

V. SUMMARY OF CLAIMED SUBJECT MATTER

The principal claim, claim 6, is directed to an isolated and purified polypeptide of *Ehrlichia canis* immunoreactive surface protein p153 encoded for by DNA selected from the group consisting of (a) isolated DNA which encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2; (b) isolated DNA differing from the isolated DNA of (a) in codon sequence due to the degeneracy of the genetic code; (c) isolated DNA sequence comprising nucleotides 1080 to 1990 of *Ehrlichia canis* immunoreactive surface protein p153 gene; (d) isolated DNA sequence comprising nucleotides 1950 to 2950 of *Ehrlichia canis* immunoreactive surface protein p153 gene; and (e) isolated DNA sequence comprising nucleotides 2940 to 4220 of *Ehrlichia canis* immunoreactive surface protein p153 gene. Support for this embodiment of the invention is found, at least on page 10, lines 1-10 and page 15, lines 12-18 of the specification.

Dependent claim 15 is directed to a composition comprising an isolated and purified polypeptide of *Ehrlichia canis* immunoreactive surface protein p153 as defined in claim 6. Support for this embodiment of the invention is found, at least on page 16, lines 5-7 of the specification.

Dependent claim 27 is directed to a polypeptide described in claim 6 that is immobilized on a surface. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 28 is directed to a polypeptide of claim 27 wherein the surface is a membrane. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 29 is directed to a polypeptide of claim 27 wherein the surface is a microtiter plate. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 30 is directed to a polypeptide of claim 6 wherein the polypeptide is an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide. Support for this embodiment of the invention is found, at least on page 12 to page 14 of the specification.

Dependent claim 31 is directed to a composition comprising the peptide of claim 30. Support for this embodiment of the invention is found, at least on page 16, lines 5-7 of the specification.

Dependent claim 32 is directed to the polypeptide of claim 30 immobilized on a surface. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 33 is directed to the polypeptide of claim 32 wherein the surface is a membrane. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 34 is directed to the polypeptide of claim 32 wherein the surface is a microtiter plate. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

VI. GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL

The issues addressed in this Appeal Brief include:

(a) Whether the written description for the sequence of an *Ehrlichia canis* immunoreactive surface protein p153 gene is sufficient under 35 U.S.C. § 112, first paragraph;

(b) Whether claims 6, 15, and 27-34 are definite relative to the sequence for an *Ehrlichia canis* p153 gene;

(c) Whether the subject matter of claim 30 directed to a full length p153 polypeptide, further limits claim 6 directed to segments of p153; and

(d) Whether sufficient antecedent basis is present for the term “surface” in claims 33 and 34.

VII. ARGUMENT

A. Rejections under 35 U.S.C. § 112

1. Claims 6, 15, and 27-34 Satisfy the Written Description Requirement of 35 U.S.C. § 112, first paragraph

Claims 6, 15, and 27-34 are rejected as failing to comply with the written description requirement because the claims allegedly contain subject matter not described in the specification in such way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. The

Action alleges that no baseline sequence is provided for the *E. Canis* immunoreactive surface protein p153 gene and none of the claimed proteins meet the written description requirement. The Action cites *Fiers v. Revel*, 984 F.2d 1164, 25 USPQ2d 1601, and *Amgen, Inc. v Chugai Pharmaceutical*, 927 F.2d 1200, 18 USPQ2d 1016, in support of the rejection. Applicants disagree.

Applicants have addressed the Examiner's concerns in their Response to Final Office Action by submitting amended claims containing a reference to GenBank accession number AF252298. However, the Examiner denied entry of these claims. Nonetheless, the presently pending claims satisfy the written description requirement.

First, it is Applicants' position that the Examiner has failed to make out a prima facie case of lack of written description. As stated in the MPEP § 2163(II)(A):

The examiner has the initial burden, after a thorough reading and evaluation of the content of the application, of presenting evidence or reasons why a person skilled in the art would not recognize that the written description of the invention provides support for the claims. There is a strong presumption that an adequate written description of the claimed invention is present in the specification as filed, *Wertheim*, 541 F.2d at 262, 191 USPQ at 96 [] The inquiry into whether the description requirement is met is a question of fact that must be determined on a case-by-case basis. . .

The MPEP also provides that an Examiner should review the entire application to understand how the applicant provides support for the claimed invention. MPEP § 2163(II)(A)(2) states:

Prior to determining whether the disclosure satisfies the written description requirement for the claimed subject matter, the examiner should review the claims and the entire specification, including the specific embodiments, figures, and sequence listings, to understand how applicant provides support for the various features of the claimed invention. . .

The present specification clearly sets forth the sequences of an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide and gene as provided in GenBank accession number AF252298. The Examiner's statement that "no baseline sequence is provided for [] the *Ehrlichia canis* immunoreactive surface protein p153 gene," does not establish prima facie a lack of written description, particularly in light of GenBank accession number AF252298. None of the reasons set forth in the Final Office Action establish any fact that would shift the burden of establishing adequate written description to the Applicants. The Examiner has failed to provide evidence or reason why the claims read in light of the specification lack written description.

Second, Applicants provide a written description for an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide and gene in the specification as GenBank accession number AF252298. The specification on page 14, line 9 to line 14 discloses the revised sequence for the *Ehrlichia canis* p153 gene and polypeptide as GenBank accession number AY156950. However, the AF252298 record was updated to include the revised sequence instead of establishing the new accession number. The current AF252298 record (Exhibit 1) states that the revised sequence (a) was submitted on September 30, 2002 and (b) replaced the earlier version of accession number AF252298 (gi:12658962; Exhibit 2). Exhibit 1 is a copy of the current GenBank entry for accession number AF252298 and Exhibit 2 is a copy of GenBank entry prior to replacement with the full length p153 sequence, each of which were made of record in Applicants' Response dated September 19, 2005. Thus, GenBank accession number AF252298 provides a baseline sequence for amino acid and nucleic acid sequences of the *E. canis* immunoreactive surface protein p153 protein and gene, respectively. One of skill in the art, based on disclosure of the nucleic acid and amino acid sequence of the *Ehrlichia canis* immunoreactive surface protein p153, i.e., GenBank accession number AF252298, had access to

the sequence of the *Ehrlichia canis* immunoreactive surface protein p153 and would have reasonably concluded that Applicants possessed the subject matter claimed as of the priority date of the present application, November 4, 2002.

In addition, the present invention is distinct from the facts underlying the *Fiers* and *Amgen* cases, which were cited in support of the rejection. In these cases the conception date of a nucleic acid sequence was the date the actual DNA sequence was known. The cases held that the description of methods for isolating a fragment of DNA and methods for isolating a corresponding mRNA is insufficient description of a nucleic acid sequence or an amino acid sequence encoded by the nucleic acid. In contrast, in the present case the DNA sequence was known and submitted to GenBank prior to the priority date of the present application. The present application does not rely on methods of isolation for identifying or describing the nucleic acid or polypeptide sequences, it discloses the sequences in the application by reference to the GenBank accession number. Therefore, the present application provides more than the mere description of the methods for isolating a DNA sequence. Thus, the holdings in *Fiers* and *Amgen* are not relevant to the present application. Because the Applicants were in possession of the invention and the GenBank accession number describes the claimed invention in sufficient detail, one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention.

Applicants note that none of the rejections speak to the insufficiency of GenBank accession number AF252298 and no notification of informalities regarding the sequence listing was conveyed to the Applicants during prosecution.

2. Claims 6, 15, and 27-34 are Definite and Satisfy the Requirements of 35 U.S.C. § 112, second paragraph

Claims 6, 15, and 27-34 are rejected under 35 U.S.C. § 112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter Applicants regard as their invention. The claims are allegedly vague and indefinite for the following reasons: (a) claim 6 does not a baseline sequence, and (b) claims 33 and 34 lack antecedent basis for “surface.”

a) Claim 6, 15, 27-34 are Definite

The Examiner alleges that no baseline sequence is provided for the claimed gene. This issue was addressed by Applicants in the claim amendments submitted in their Response After Final Office Action by including a reference to GenBank accession number AF252298. The amendment was not entered by the Examiner. Nonetheless, as discussed above and incorporated here by reference, one of skill in the art reading the claims in light of the specification would have readily recognized the baseline sequence of the *E. canis* immunoreactive surface protein p153 as GenBank accession number AF252298. The pending claims satisfy 35 U.S.C. § 112, second paragraph.

b) Claims 33 and 34

The Examiner indicates that claims 33 and 34 lack antecedent basis for the term “surface.” Again, Applicants addressed this rejection in amendments not entered by the Examiner. However, this insufficiency is easily addressed by clarification of claim dependency and Applicants can address upon remand to the Examiner.

B. Objections under 37 C.F.R. § 1.175

1. Claim 30 Further Limits the Subject Matter of Claim 6

Claim 30 is objected to as failing to further limit the subject matter of a previous claim. Applicants respectfully disagree.

Claim 30 does further limit the subject matter of claim 6. Claim 6 is directed to segments of the *E. canis* p153 protein and reads in part "...isolated DNA which encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2." SEQ ID NO:2 represents a segment of the P153 protein. Claim 30 is directed to the full length *E. canis* protein and reads "The isolated and purified polypeptide of claim 6, wherein the polypeptide is an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide." The full length *E. canis* p153 protein is described in the specification on page 14 that reads:

Anti-p43 antibody reacted with a native protein of approximately 200 kD in *E. canis* whole cell lysates. Furthermore, this 200 kD protein was also recognized by sera from an *E. canis* infected dog (Figure 5). A partial gene sequence previously identified as p43 (N-terminal portion of the p153) assigned GenBank accession number AF252298. The amended sequencing encoding p153 was assigned the GenBank accession number AY156950.

GenBank accession number AF252298 was amended to encompass the sequence of GenBank accession number AY15690, see above for a more detailed discussion. GenBank accession AF252298 describes the full length *E. canis* p153 polypeptide. The polypeptide segments of claim 6, in particular the segment having the amino acid sequence of SEQ ID NO:2, are not equivalent to the *Ehrlichia canis* immunoreactive surface protein p153 polypeptide of claim 30. Thus, claim 30 is distinct from and further limits the claim 6 to the full length polypeptide sequence.

2. Claims 31, 32, 33, and 34 are Distinct from Claims 15, 27, 28, and 29

Claims 31, 32, 33 and 34 are objected to as being substantial duplicates of claims 15, 27, 28, and 29. This objection is related to the previously argued objection related to the alleged failure to further limit the subject matter of a previous claim. The arguments set forth above relating to the objection of claim 30 are incorporated here by reference. Since claim 30 is distinct from claim 6, claims 31, 32, 33, and 34, which depend from claim 30, are distinct from claims 15, 27, 28, and 29, which depend from claim 6.

C. Grouping of Claims


The evidence of record overwhelmingly indicates that the present invention satisfies the requirements under 35 U.S.C. § 112. In particular, GenBank accession AF252298 describes the amino acid and nucleic acid sequence of the *E. Canis* immunoreactive surface protein p153 and provides a basis for nucleic acid and amino acid sequences presently claimed. The claims stand or fall together.

D. Conclusion

For the above-argued reasons, Appellants respectfully request that the rejection of claims 6, 15, and 27-34 be reversed. Appellants have provided arguments that overcome the pending rejections. Appellants respectfully submit that the Examiner's conclusion that the claims should be rejected is unwarranted.

It is therefore again requested that the Board overturn the Examiner's rejection.

Respectfully submitted,



Charles P. Landrum
Reg. No. 46,855
Agent for Appellants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201
(512) 536-4598 (facsimile)

Date: September 21, 2006

VIII. CLAIMS APPENDIX

6. (Previously presented) An isolated and purified polypeptide of *Ehrlichia canis* immunoreactive surface protein p153 encoded for by DNA selected from the group consisting of:

(a) isolated DNA which encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2;

(b) isolated DNA differing from the isolated DNA of (a) in codon sequence due to the degeneracy of the genetic code;

(c) isolated DNA sequence comprising nucleotides 1080 to 1990 of *Ehrlichia canis* immunoreactive surface protein p153 gene;

(d) isolated DNA sequence comprising nucleotides 1950 to 2950 of *Ehrlichia canis* immunoreactive surface protein p153 gene; and

(e) isolated DNA sequence comprising nucleotides 2940 to 4220 of *Ehrlichia canis* immunoreactive surface protein p153 gene.

15. (Previously presented) A composition comprising a p153 polypeptide of claim 6.

27. (Previously Presented) The isolated and purified polypeptide of claim 6, wherein the protein is immobilized on a surface.

28. (Previously Presented) The isolated and purified polypeptide of claim 27, wherein the surface is a membrane.

29. (Previously Presented) The isolated and purified polypeptide of claim 27, wherein the surface is a microtiter plate.

30. (Previously Presented) The isolated and purified polypeptide of claim 6, wherein the polypeptide is an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide.
31. (Previously Presented) A composition comprising a p153 polypeptide of claim 30.
32. (Previously Presented) The isolated and purified polypeptide of claim 30, wherein the protein is immobilized on a surface.
33. (Previously Presented) The isolated and purified polypeptide of claim 30, wherein the surface is a membrane.
34. (Previously Presented) The isolated and purified polypeptide of claim 30, wherein the surface is a microtiter plate.

IX. EVIDENCE APPENDIX

Exhibit 1 – Copy of GenBank accession number AF252298 (gi:37528969), made of record in Applicants Response dated September 19, 2005 to the non-final Office Action mailed April 25, 2005 as Exhibit 2.

Exhibit 2 – Copy of GenBank accession number AF252298 (gi:12658962), made of record in Applicants Response dated September 19, 2005 to the non-final Office Action mailed April 25, 2005 as Exhibit 1.

EXHIBIT 1

NCBI Nucleotide

My NCBI (Sign In) (Register)

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search for

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Display Show [Send to](#)

Range: from to ☐ Reverse complemented strand Features: ☐ SNP ☒ CDD ☐ F

☐ 1: AF252298. Reports Ehrlichia canis 2...[gi:37528969]

[Links](#)

[Comment](#) [Features](#) [Sequence](#)

LOCUS AF252298 4266 bp DNA linear BCT 06-OCT-2003
DEFINITION Ehrlichia canis 200 kDa immunoreactive glycoprotein gene, complete cds.

ACCESSION AF252298

VERSION AF252298.2 GI:37528969

KEYWORDS

SOURCE Ehrlichia canis

ORGANISM

Ehrlichia canis
Bacteria; Proteobacteria; Alphaproteobacteria; Rickettsiales;
Anaplasmataceae; Ehrlichia.

REFERENCE 1 (bases 1 to 4266)

AUTHORS McBride, J.W., Corstvet, R.E., Breitschwerdt, E.B. and Walker, D.H.

TITLE Immunodiagnosis of Ehrlichia canis infection with recombinant proteins

J. Clin. Microbiol. 39 (1), 315-322 (2001)

PUBMED 11136790

REFERENCE 2 (bases 1 to 4266)

AUTHORS McBride, J.W., Comer, J.E. and Walker, D.H.

TITLE Novel Immunoreactive Glycoprotein Orthologs of Ehrlichia spp

Ann. N. Y. Acad. Sci. (2003) In press

REFERENCE 3 (bases 1 to 4266)

AUTHORS McBride, J.W. and Walker, D.H.

TITLE Direct Submission

JOURNAL Submitted (04-APR-2000) Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA

REFERENCE 4 (bases 1 to 4266)

AUTHORS McBride, J.W. and Walker, D.H.

TITLE Direct Submission

JOURNAL Submitted (30-SEP-2002) Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA

COMMENT On Oct 6, 2003 this sequence version replaced gi:12658962.

FEATURES

source

Location/Qualifiers

1..4266

/organism="Ehrlichia canis"

/mol_type="genomic DNA"

/db_xref="taxon:944"

1..4266

/note="gp200"

/codon_start=1

/transl_table=11

/product="200 kDa immunoreactive glycoprotein"

/protein_id="AAK01145.2"

/db_xref="GI:37528970"

[CDS](#)

```

/translation=*MSDPKQGSPEHQNTNPSDDIQDQSQQQQQBQDQQQ3AVGVAVSH
SPIERERVAAPESRDLYTVIIPKQKGTAPILERKSPITPEKFEVBUDEDLPFTLPFKTY
SGRGYDDVCVSMPTVSBGTYQPTVQGSNLYSSIGGVQKQAQYDAARAAGPRKFLG3
PYT78NQGEIMDFPDTFPMFSDWRNVLGNKEIKEMKLTSGPVROIADRIVASGEGLS
BDQVEEILDIIPMBSEIABGINSPLIADVDNMFVKGAHNMVLMHLVTAACDVCPRI
KALGEVDEDEGLGANAYNVLCDSRQNTLPLEHAAMKCTGDKLKLCKEKTETDTITANF
ANQSPLEHITQKPPDCSVLDIEEFTSENLDPFLVCGDGQKPLHAHVBHLPPVILKSMVD
EYKNSBPFOI.VNRPDYFQNTI.AHYAVKQNMADUTLFWMLKASGADLAVRNVVGRAPL
KVASNAGKANAVSGLVSCIDVNSGVNQDTFLHIAVEGGSMBTFLAVLNKRGADVSF
QINDGVTFMLSAARYGDIGVILKALGSAKPHIKGEITVAKSILMBDYKGTPLHFWVAG
GSRDTFRVVKQYKCKIDLATIRALMQQRSGGELVNLGDFESENTLQSPMAKFLQHI
QSANFGVSPARKGI.VSSNMFVMDKTLNFWGDSILHLPSEGYKAMQVAALFDCKEAVEM
LAKSAKPSDILPKTSATPTPLNLACLSDOMEVVRGLVVGQSIDINCRSGSDKNTVLEY
ATSKGDSFLVQKILAHITGVNVNCEHNLQQTPLHLAVBGQDPKYVSSILKAGAVNRLDK
DNKSGVLSAIVPQKKEKQVILGVNKLIDREADINLDDHNLFLDQCLSGQVNMRLDK
LLCQGVNVNMSRTFMVYAAI.SENHAIKSLASAGQVNVREVMNPSRHSJHFLMV
AVADGNAGLLKTLVBSQCDVEKSKCKGTALNAYSHONKXGNKAIKIISHSWGT
NRDIUTQNRNAGTPLHRLKSGNTNSVQNTLSAHPRTAKELLTARDKBYTTHGTT
VGVNVDVNSIILESNLSKGVNHLSEIVNAGSGWFTPLAIAKISGDYRANMIGSL
EKTLESLBLQUTDINGDTPLRLSCQSGNVNTPQPLGLDQLDRLPLXTLKTANXNDPT
LHDAIRHDDIKSANNMKNCKMKRLAVLXCTDSFGHTVLTITADQVIANPSEKXDL
GLMOTAVXRLKQGLKDLVNTNRNSEDUTVACALLSDNKYAKRLKXSHDITLVRGHS
NHQSLBCTRDDSKIKKSIIVSKSLPFLKIKIPARAASGYRLESLIESCDSDVSEVET
NLETSAVNPVSSGAVPKVEVQRTNVDSGPEDESLELRLESDLSGSDFDQRMAD
LDQRIANTVGLPEVTVQVAVSGQQAASPSGQJAGVQCKEMQK*

```

ORIGIN

```

1 atgtcagatc ccaaacagg tgcaccagaa caaatcaaaa ctaccctatg tgggtgatatt
61 caggatccaa gtccagcaaga tcaacaggaa cagcaggagg agctggaggt agtbtgggat
121 gotgttggtt atagtcccat tgaagaggag agcgtgucgt ctactgagag cgaagattta
181 tatacctgta ttatacctaa ggytaaaaga actcgtgctc caatttggg aagaagatct
241 cctactccctg aacggaaggt gaagatagat gaagattaac ctactacatt accgcgaaga
301 acattttctag gagaagyaat tgaatgagtt ggaagttaga tgcctactgt tctgtctggc
361 atatacccaat ctccnatagt tcaagatagt aattctatatt caagtattgg tggcgtatcc
421 caaagaagcag aatatgatgc agcagctcgg cctggtgggg cagaagaagt ttgtattggg
481 ceatatcatc tcaagatagg tcaagaaatt atggactttg aatttgatac tcccttggcc
541 gatgttagga atgagctttt aggtataaaa gagataaag agagatgggt taactcttct
601 gyyccgctac gtgatattgc tgaatggata gtrggtctc aagytgattt gctgaggagt
661 caagttagag aatcccttga tattaatttt atgtcgaatt cagaatacgg tgaaggtatt
721 tctaatccat taactgctga tcttgataat aatccgttta aggttgctaa gactgtgatn
781 aeatctgagc atctagttta tgccttgcat gttgatccac gttatagtaa agctttagga
841 gaggtggaaa atgatgaagg tgatttagga gctaatcggt ataagtgttt agatattgag
901 ggtaatctctv ctttacctca tgcctgaagg aattgtacag ggcgttaagt aaggttttgt
961 atggagaaaa caaagactga ttttatgtat actgaaattt ttggaarcaa atccenttta
1021 catatgtaata cactgaagcc agattgttct gattagata ttgaagagt ttcaacgcgt
1081 aatttgagtt ttggagctgt agatgggagt ggtataaaat ctttaccata tctgtgttaa
1141 catctgcac ctgtataact taaggcgata atggaacatg taataaatag tagtactgtt
1201 caagatttag taatatgtcc tgaattattt ggaaatacta tagetcaata tgcagcttaag
1261 atataaaatct ctgattttaa atgtgtttaa atcgtgaaag cttcaggagc tgaattaaat
1321 gttgaagaatg tagttggtag agctccaata catgttgctt cttctaatga taaggctaat
1381 gtagttcttg gacttgata atcgtgtatt gacgttaatt ctcaagatg gaactggagt
1441 acaacacatcc atattgctgt tgaaggcggt agtatggaga cgggtattag atcgttaaat
1501 cagagaggctg ctgattgtta gtccaaagat aaacatggag ttacacatct gcttgatagt
1561 gctaaatatgt gatatataga tgtaataaaa gctttaggtt cagctaaanc aaatatttaa
1621 ggtgaagacc ctgttgctaa atcattgctg atgggagatt acaaaggttt taacaccttg
1681 ctttttgtag ctggttggtg tagcagagat acattccgtt tcttaagaaa aaattttgaa
1741 aaatgctaat acttagctac tattanggca gctttaatg aagatagaag tgggtggtag
1801 ctgttaaat ttgagggatt tgaagattga aatatattg gttcgcnaa tgcnaaatct
1861 ttgcagacata ttcaatcaga aaatttttgt ttcttccag cgcgaagggg tatagatagt
1921 tctaatcaaca atgtataatga agatatctta aattttgctt ggaattcctt acacatacca
1981 agtgagagtg ggtataatgc aatgcaggtt gctgctttgt ttggtgacaa agaagcagtg

```

```

2041 aaaaatgcttg ctaaaagtgc taagccaaagt gatcttaatt ttaagaette agcaactcct
2102 atctcgttaa atcttgcatg tcttagaggt gataatgagg tagtacctgg gtttagaggt
2161 caacatggta ttgacattaa ccaacgtatg ggaagtgata asaactcgtg attgcatatt
2221 gcaatcagca aaggagatag ttctcttgty caaaagatat tagctcctac tggagttgat
2281 gctaatgttg agaataacct aggtcaaaaog cctttacact tagcagttga gggaggagat
2341 cctaaagatag tatcttctct tcttaaaagt ggtgcagrag ttaactgctc ggaigatcat
2401 ggtagatctg tactttcttc tgcgatagtt ccaggtagaa aagaaaaggg agtgcctggg
2461 atagttaata aattgctgga tagaggtgca gatcttaatt tagctggaga ccaaatata
2521 ctttttgatc agtgcttaag ggtggatat aataatgtat tajtatagtt aatcaacaa
2581 ggggttgagg ttaatcgaaa tagtgaataa cgtccaaatg tttatgctgc aatatcttgg
2641 aatgagcatg ctatacaaat attagctaat gctgggtggag atgttaattg agtcttaatt
2701 aatcaatcta gtaggcatc aggaatactt ttaattatgg tgcagtagc agatggttaatt
2761 gctggctctc ttaaaacatt agtttctgaa ggtatgtgat tgggttaatt tggaaaagat
2821 ggttaacagc agttacatta tgcgttagt cactcagata aagagtttgg taataaagct
2881 ataaagatat taatttcaag taatagtgtr gggactaata gagatattct tactcaaaag
2941 aataacgcag gtgataccac ttacatgaa gctcttaagt caggttaatt taattctgta
3001 cagatattct taagtctgt acatcaaga taagcaaaag agatattaat agccagagac
3061 aagaagaggt acacaacaaat gcaattactt gttggagtaa ataattgtga tgttggtaga
3121 agtattctag agtctatgct ctctaaaggt gtgtaataat tgggagagat tgttggagca
3181 caggaatgta atttogaac acactgcat gctgcatata aaatctctga ttatctgctt
3241 cgggaactga taataggtag ctatagaaa acagaattgt caaagttatc gaatttaaca
3301 gatattcaag gggataccac actacatctt tcttgtcagt ctggttaatt cgagattgaa
3361 caattctctc ttggagggtt ggataaaagt gaattaccta agaatattaa gtagagcaat
3421 aaaaatggag ataactcttt acatgatgct ataagaaagt atgatattaa atcagaaaaa
3481 atgatgatta ggaattgtta caaagaagaa ctgcataat tattaaatg taagatagtt
3541 ttggtaata cagttattga tactattgct gaaccaagta tggagaatca agaatcaag
3601 aagaacattg atgggttgat gaatttagca gtgaaaaggc taagaatata agatctgaaa
3661 gatcttgata atcagcgaaa taactctgac gatactgttg caattgtgct tcttttaccg
3721 gatagtaaat atgctcaaaa gatacttaaa tcatgtaac atgatcaatt agtgagagga
3781 aatagtaata atcaatcttt atcagagctg attcgtgat atagtaataa taaaaaaggt
3841 ggaattctta gtaagtcttt attttcaaaa ttaagaagaa ttgaggcaag agotgcacg
3901 gtatgatttg aagaattctc tagtatcagt agtggtagtg atgtctcttc tgaatacaaa
3961 aatagtaagc agtaagtgc agtacctgaa gtgagcaaaa gtatgggtgc tgtgtctctc
4021 aaaaatgtgc aagaaaacag agttgacacg tctggctctt ctgatataga aagtttagag
4081 agattatctg atactagctt tgggtcaaat gattctgctc agcgaatgag agattttagt
4141 caagaaatag caaatattgt tagtgggtta ccagagttka cccaggttagc tgaagtcaaa
4201 caacaagcag catctcttag ttcaagttca gctgttgctg tcaacaaaaa agagatgcag
4261 agataa

```

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

EXHIBIT 2

NCBI Nucleotide (Standard) Register

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search Nucleotide for

Limits Preview/Index History Clipboard Details

Display GenBank Show 5 Send to

Range: from begin to end ☐ Reverse complemented strand Features

☐ 1: AF252298. Replaces ...[gi:12658962] The record has been replaced by 37528969

Comment Features Sequence

LOCUS AF252298 1173 bp DNA linear BCT 05-FEB-2001

DEFINITION Ehrlichia canis 43 kDa surface protein gene, complete cds.

ACCESSION AF252298

VERSION AF252298.1 GI:12658962

KEYWORDS

SOURCE

ORGANISM Ehrlichia canis

Bacteria; Proteobacteria; Alphaproteobacteria; Rickettsiales; Anaplasmataceae; Ehrlichia.

REFERENCE 1 (bases 1 to 1173)

AUTHORS McBride, J.W., Corstvet, R.E., Breitachwerdt, E.B. and Walker, D.H.

TITLE Immunodiagnosis of Ehrlichia canis infection with recombinant proteins

JOURNAL J. Clin. Microbiol. 39 (1), 315-322 (2001)

PUBMED 11136799

REFERENCE 2 (bases 1 to 1173)

AUTHORS McBride, J.W. and Walker, D.H.

TITLE Direct Submission

JOURNAL Submitted (04-APR-2000) Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA

COMMENT [WARNING] On Oct 6, 2003 this sequence was replaced by a newer version gi:37528969.

FEATURES

source Location/Qualifiers

1..1173

/organism="Ehrlichia canis"

/mol_type="genomic DNA"

/db_xref="taxon:944"

CDS 1..1173

/codon_start=1

/transl_table=1

/product="43 kDa surface protein"

/protein_id="AAKJ1145.1"

/db_xref="GI:12658962"

/translation="MSDFKGGDPEQNGTNPSEGIQDGSQEQBQCGQSGAVG3AVGN
SPIERVAAPESEDLTVIIIFKQKTAAPILERSKFTPEFVDELGDLFFTLAPFTF
SGENYDVGSRNFTVSRGIKQFFIVQDSNLYSSISGVFGNQIDMAADQCFKFLYQ
PTTPBNQGLINDFTFTWETFRANVLRKEIKENLTSCFFRDYADRIIVAKKCLG
EDQVSEILDITPPESSITARDISNPLHADVDNPPKADQNFNLSLIVACDDVPPIV
KALCEVNDKCDLGAAHWLSEKTLPLHKAQSKCTDCLKLQVETTKTQPIYVNP
ANQSPILHTITGPDCEVLDIEFTSRMLDRGITDQDKNPIHRAVHHLPVNLKGR"

ORIGIN

1 atgtcagatc caccaccagg tgcaccgga caccaccga caccaccga tggatgatatt
61 caggaccaga gtcacagga taccaccgga caccaccga caccaccga cgtcggggt

```

121 gctgttggta atagtccat tgaagagag agagtagct ctcctgagag tgaagattta
181 tatactgtga ttataccraa gggtaaaaga atgtctgctc caattttggg aagaagatct
242 cctactcctg aacggaagat agagatgat gaagatttac ctctacac cccgcaaga
301 acattctcag gagaaggata tgaatgaagt ggaattagta tgcctactgt tagctgtggc
361 atataccaac ctcccatagt tcaagatagt aatctatatt caagtalagg tggcgtacca
421 caagaagcac aatatgatgc agcagctcgg gctggcgggc caagaaagct tttgatggg
481 ccacatacat tcaatgaatg tcaggaaatt atggactctg aatttgatgc tctctgcca
541 gatgttagga atgcagtttt aggtaaataa gagataaag agagtgattt aactactctt
601 gggccagtac gtgactatgc tgaaggata gtgtcttcta agagtgattt gctgaggat
661 cagtagaag aaatccttga ttttatattt atgactgaat cagaaatcgc tgaaggatc
721 tctaaacaa taactgttga tttagaatt aatccctgta aagtgctaa gaatgtgat
781 acattgatgc atcagttta tgcattgat gtgtaccac gataagtaaa agcttagga
841 gaggtagaaa atgataagg tgatttagga cctaatcctt aaatgvttt agatagtag
901 ggtactcttc cttacatcca tgcctcaag aattgtacag ggaatagttt aagactttgt
961 acgagaaaa caagaactga ttttatgac actgcaaat ttgagatca atccctttt
1021 catattatta caagaagcc agattgtctt glattagata ttgagagctt tacaagcgt
1081 aatttagatt tggactctg agatggagag ggtaaaato cttacatca tgcctgtga
1141 catttgcac cgttaactt aaaggggccc taa

```

//

Disclaimer | Write to the Help Desk
 NCBI | BLAST | NCB

X. RELATED PROCEEDINGS APPENDIX

NONE.